A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment (Q39200135)

9 September 2017

title

A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment (English)

1 reference

9 September 2017

1 reference

Uri Tabori

1 reference

9 September 2017

Cynthia Hawkins

1 reference

9 September 2017

Scott Ryall

1 reference

9 September 2017

publication date

25 March 2017

1 reference

9 September 2017

published in

Brain Tumor Pathology

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

51-61

1 reference

Epidemiology of childhood cancer

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Diffuse glioma growth: a guerilla war

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Histologic classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Oligodendroglioma: pathology, molecular mechanisms and markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Low-grade astrocytomas in children: evolving management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 and IDH2 mutations in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Molecular markers in low-grade gliomas: predictive or prognostic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Molecular Classification of Low-Grade Diffuse Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

IDH1/2 mutation detection in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Genetic alterations in pediatric high-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Raf kinases in cancer-roles and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Mutation analysis of B-RAF gene in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Targeting BRAF in pediatric brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Role of the p16 tumor suppressor gene in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

A distinct spectrum of copy number aberrations in pediatric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Clinical and molecular characteristics of malignant transformation of low-grade glioma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Evidence of H3 K27M mutations in posterior fossa ependymomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-017-0282-Z

10.1007/S10014-017-0282-Z

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference